Systemic Nonarticular Manifestations of Rheumatoid Arthritis: Focus on Inflammatory Mechanisms

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 2, 2009, Pages 132-143

  Moreland, Larry W ^a   Curtis, Jeffrey R ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

complications; cytokines; extra articular; IL 6; manifestations; nonarticular; pro inflammatory; RA; rheumatoid arthritis; systemic; TNF

Indexed keywords

ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HEPCIDIN; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 7; IRON; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANEMIA; ATHEROSCLEROSIS; BLEEDING; BRONCHIOLITIS OBLITERANS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DOWN REGULATION; ENDOTHELIUM; FATIGUE; FELTY SYNDROME; HUMAN; INFLAMMATION; KERATITIS; KERATOCONJUNCTIVITIS SICCA; LUNG DISEASE; LYMPHADENOPATHY; MEDLINE; NEUTROPENIA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCLERITIS; SIDE EFFECT; SOCIAL PSYCHOLOGY; SURVIVAL; T LYMPHOCYTE; THROMBOCYTOPENIA; UPREGULATION; UVEITIS;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INFLAMMATION; MEDLINE;

EID: 70349408821     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.08.003     Document Type: Review

References (82)

1. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., and Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29 (2002) 62-67
2. Wilson A., Yu H.T., Goodnough L.T., and Nissenson A.R. Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am J Med 116 Suppl 7A (2004) 50S-57S
3. Turesson C., O'Fallon W.M., Crowson C.S., Gabriel S.E., and Matteson E.L. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 62 (2003) 722-727
4. Feldmann M., Brennan F.M., and Maini R.N. Rheumatoid arthritis. Cell 85 (1996) 307-310
5. Anaya J.M., Diethelm L., Ortiz L.A., Gutierrez M., Citera G., Welsh R.A., et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24 (1995) 242-254
6. Cohen M.G., Li E.K., Ng P.Y., and Chan K.L. Extra-articular manifestations are uncommon in southern Chinese with rheumatoid arthritis. Br J Rheumatol 32 (1993) 209-211
7. Cohen S.B., Moreland L.W., Cush J.J., Greenwald M.W., Block S., Shergy W.J., et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 63 (2004) 1062-1068
8. Goldring S.R., and Gravallese E.M. Adverse effects of rheumatoid arthritis on bone remodeling. Arthritis Res Ther 6 (2004) 38
9. Jongen-Lavrencic M., Peeters H.R., Wognum A., Vreugdenhil G., Breedveld F.C., and Swaak A.J. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol 24 (1997) 1504-1509
10. Pollard L.C., Choy E.H., Gonzalez J., Khoshaba B., and Scott D.L. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 45 (2006) 885-889
11. Riemsma R.P., Rasker J.J., Taal E., Griep E.N., Wouters J.M., and Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 37 (1998) 1042-1046
12. Turesson C., Jacobsson L., and Bergstrom U. Extra-articular rheumatoid arthritis: prevalence and mortality. Rheumatology (Oxford) 38 (1999) 668-674
13. Wolfe F., and Michaud K. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol 31 (2004) 2115-2120
14. Wolfe F., and Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 33 (2006) 1516-1522
15. Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O'Fallon W.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 48 (2003) 54-58
16. Voulgari P.V., Kolios G., Papadopoulos G.K., Katsaraki A., Seferiadis K., and Drosos A.A. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 92 (1999) 153-160
17. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
18. Davis M.C., Zautra A.J., Younger J., Motivala S.J., Attrep J., and Irwin M.R. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 22 (2008) 24-32
19. Glossop J.R., Dawes P.T., Hassell A.B., and Mattey D.L. Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes. J Rheumatol 32 (2005) 1673-1678
20. Maury C.P., Liljestrom M., Laiho K., Tiitinen S., Kaarela K., and Hurme M. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis. Arthritis Rheum 48 (2003) 3068-3076
21. Papadaki H.A., Kritikos H.D., Valatas V., Boumpas D.T., and Eliopoulos G.D. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100 (2002) 474-482
22. Weinstein D.A., Roy C.N., Fleming M.D., Loda M.F., Wolfsdorf J.I., and Andrews N.C. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100 (2002) 3776-3781
23. Pietrangelo A., and Trautwein C. Mechanisms of disease: the role of hepcidin in iron homeostasis-implications for hemochromatosis and other disorders. Nat Clin Pract Gastroenterol Hepatol 1 (2004) 39-45
24. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
25. Kaltwasser J.P., Kessler U., Gottschalk R., Stucki G., and Moller B. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28 (2001) 2430-2436
26. Mercuriali F. Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Semin Hematol 33 (1996) 18-20 discussion 21
27. Han C., Rahman M.U., Doyle M.K., Bathon J.M., Smolen J., Kavanaugh A., et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 34 (2007) 2177-2182
28. Franck H., Rau R., and Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 15 (1996) 163-167
29. Grove M.L., Hassell A.B., Hay E.M., and Shadforth M.F. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94 (2001) 309-319
30. Hamaguchi M., Kawahito Y., Ishino H., Yoshida M., and Yoshikawa T. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol 26 (2007) 988-990
31. Pathare S.K., Heycock C., and Hamilton J. TNFalpha blocker-induced thrombocytopenia. Rheumatology (Oxford) 45 (2006) 1313-1314
32. Kirwan J.R., Minnock P., Adebajo A., Bresnihan B., Choy E., de Wit M., et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 34 (2007) 1174-1177
33. Hewlett S., Hehir M., and Kirwan J.R. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 57 (2007) 429-439
34. Mancuso C.A., Rincon M., Sayles W., and Paget S.A. Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. J Rheumatol 33 (2006) 1496-1502
35. Maini R.N., Taylor P.C., Szechinski J., Pavelka K., Broll J., Balint G., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 (2006) 2817-2829
36. Moreland L.W., Genovese M.C., Sato R., and Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum 55 (2006) 287-293
37. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
38. Kanis J.A., Johansson H., Oden A., Johnell O., de Laet C., Melton I.L., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 (2004) 893-899
39. Fonseca J.E., Cortez-Dias N., Francisco A., Sobral M., Canhao H., Resende C., et al. Inflammatory cell infiltrate and RANKL/OPG expression in rheumatoid synovium: comparison with other inflammatory arthropathies and correlation with outcome. Clin Exp Rheumatol 23 (2005) 185-192
40. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203 (2006) 2673-2682
41. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., and Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32 (2003) 1-7
42. Abramson S.B., and Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 41 (2002) 972-980
43. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S., and Duff G.W. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2 (1988) 706-709
44. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., and Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35 (2004) 1200-1207
45. Suematsu A., Tajiri Y., Nakashima T., Taka J., Ochi S., Oda H., et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 17 (2007) 17-23
46. Kim M.S., Day C.J., Selinger C.I., Magno C.L., Stephens S.R., and Morrison N.A. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase. NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem 281 (2006) 1274-1285
47. Guler-Yuksel M., Bijsterbosch J., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Hulsmans H.M., de Beus W.M., et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 67 (2008) 823-828
48. Chopin F., Garnero P., le Henanff A., Debiais F., Daragon A., Roux C., et al. Long term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008) 353-357
49. Pixley J.S., and Patchin G.M. Felty's syndrome. BioDrugs 7 (1997) 356-365
50. Bowman S.J., Hall M.A., Panayi G.S., and Lanchbury J.S. T cell receptor alpha-chain and beta-chain junctional region homology in clonal CD3+, CD8+ T lymphocyte expansions in Felty's syndrome. Arthritis Rheum 40 (1997) 615-623
51. Meliconi R., Uguccioni M., Chieco-Bianchi F., Pitzalis C., Bowman S., Facchini A., et al. The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome. Clin Exp Rheumatol 13 (1995) 285-291
52. Sordet C., Gottenberg J.E., Hellmich B., Kieffer P., Mariette X., and Sibilia J. Lack of efficacy of rituximab in Felty's syndrome. Ann Rheum Dis 64 (2005) 332-333
53. Ghavami A., Genevay S., Fulpius T., and Gabay C. Etanercept in treatment of Felty's syndrome. Ann Rheum Dis 64 (2005) 1090-1091
54. del Rincon I.D., Williams K., Stern M.P., Freeman G.L., and Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001) 2737-2745
55. Turesson C., Jarenros A., and Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 63 (2004) 952-955
56. Turesson C., McClelland R.L., Christianson T.J., and Matteson E.L. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 70-75
57. De Pablo P., Dietrich T., and Karlson E.W. Antioxidants and other novel cardiovascular risk factors in subjects with rheumatoid arthritis in a large population sample. Arthritis Rheum 57 (2007) 953-962
58. Roman M.J., Moeller E., Davis A., Paget S.A., Crow M.K., Lockshin M.D., et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144 (2006) 249-256
59. Dessein P.H., Joffe B.I., and Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 7 (2005) R634-R643
60. Lindmark E., Diderholm E., Wallentin L., and Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 286 (2001) 2107-2113
61. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
62. Gerli R., Sherer Y., Bocci E.B., Vaudo G., Moscatelli S., and Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann NY Acad Sci 1108 (2007) 372-381
63. Choi H.K., and Seeger J.D. Lipid profiles among US elderly with untreated rheumatoid arthritis-the third National Health and Nutrition Examination Survey. J Rheumatol 32 (2005) 2311-2316
64. Boers M., Nurmohamed M.T., Doelman C.J., Lard L.R., Verhoeven A.C., Voskuyl A.E., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 842-845
65. Allanore Y., Kahan A., Sellam J., Ekindjian O.G., and Borderie D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 365 (2006) 143-148
66. Popa C., Netea M.G., Radstake T., Van der Meer J.W., Stalenhoef A.F., van Riel P.L., et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 64 (2005) 303-305
67. Seriolo B., Paolino S., Sulli A., Fasciolo D., and Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 1069 (2006) 414-419
68. Tam L.S., Tomlinson B., Chu T.T., Li T.K., and Li E.K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26 (2007) 1495-1498
69. van Halm V.P., Nurmohamed M.T., Twisk J.W., Dijkmans B.A., and Voskuyl A.E. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8 (2006) R151
70. Hurlimann D., Forster A., Noll G., Enseleit F., Chenevard R., Distler O., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106 (2002) 2184-2187
71. Jacobsson L.T., Turesson C., Gulfe A., Kapetanovic M.C., Petersson I.F., Saxne T., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 1213-1218
72. Dixon W.G., Watson K.D., Lunt M., Hyrich K.L., Silman A.J., and Symmons D.P. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56 (2007) 2905-2912
73. Liang K.P., Liang K.V., Matteson E.L., McClelland R.L., Christianson T.J., and Turesson C. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum 54 (2006) 642-648
74. Gonzalez A., Maradit Kremers H., Crowson C.S., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-RA patients?. Ann Rheum Dis 67 (2008) 64-69
75. Prada J., Noelle B., Baatz H., Hartmann C., and Pleyer U. Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Br J Ophthalmol 87 (2003) 548-550
76. Atchia I.I., Kidd C.E., and Bell R.W. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol 12 (2006) 291-293
77. Fujita M., Igarashi T., Kurai T., Sakane M., Yoshino S., and Takahashi H. Correlation between dry eye and rheumatoid arthritis activity. Am J Ophthalmol 140 (2005) 808-813
78. Bilgici A., Ulusoy H., Kuru O., Celenk C., Unsal M., and Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 25 (2005) 429-435
79. Turesson C., Matteson E.L., Colby T.V., Vuk-Pavlovic Z., Vassallo R., Weyand C.M., et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum 52 (2005) 73-79
80. Atkins S.R., Turesson C., Myers J.L., Tazelaar H.D., Ryu J.H., Matteson E.L., et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum 54 (2006) 635-641
81. Wolfe F., Caplan L., and Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol 36 (2007) 172-178
82. Dixon W.G., Watson K.D., Lunt M., and Hyrich K.L. Rheumatoid arthritis, interstitial lung disease, mortality and anti-TNF therapy: results from the BSR Biologics Register (BSRBR). ACR/ARHP Annual Scientific Meeting 2007. Boston (MA) (November 6-11, 2007) (Abstract)